Guest Speaker

Jackie Whitesell, MD
Platform Trial Site Investigator
Saint Alphonsus Regional Medical Center, Boise ID
SAINT ALPHONSUS NEUROLOGY
ALS CLINIC

[Map showing locations of clinics across the United States]
ABOUT US

Our clinic serves patients in Idaho, Oregon, and Nevada. We serve a rural population.

We have 7 neurologist plus 2 neuro-hospitalists.

We have a monthly multidisciplinary ALS team

We have a dedicated neurology research coordinator.
ALS
Healey Platform trial

MS
MS registry COREVITAS
OUR TEAM

PHYSICAL THERAPIST (LIZ ARMSTRONG)
RESPIRATORY THERAPY (JAMIE GRANDSTAFF)
SPEECH THERAPY (SUZANNE NEIDERMEYER)
MEDICAL ASSISTANT (TRISHIA STREET)
RESEARCH COORDINATOR (JOSHUA HARRISON)
MEDICAL EQUIPMENT/LOAN CLOSET (SHANE DAVIS AND MIKE MCHARGUE)
ALSA CARE SERVICE COORDINATOR (HEIDI FRANTZ)
FUTURE DIRECTIONS/GOALS

**GRANTS**

We are applying for grant funding to help with patient travel expenses to clinical trial sites.

**OUTREACH CLINIC**

I have taken a part-time position at VA Boise and see ALS there.

**DIETICIAN AND SOCIAL WORK**

We are working to fill both needs.
The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial

Screening

Regimen Assignment

(n=160 for each regimen)

Regimen A

Regimen B

Regimen C

Regimen D

Regimen E

3:1 Randomization within each Regimen

(n=120 for active drug; n=40 for placebo)

Zilucoplan

Placebo

Verdiperstat

Placebo

CNM-Au8

Placebo

Pridopidine

Placebo

Trehalose

Placebo

Shared Placebo

Open Label Extension
Enrollment Updates (as of June 23, 2022)

- **82** individuals have signed informed consent
- **50** individuals have been randomized within Regimen E

Thank You

This breakthrough trial would not be possible without your participation.

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS.

Every research participant, **whether on the active drug or placebo, plays a critical role** in making the hope of finding a cure for ALS a reality.
New Resource

- Printer-friendly “Evergreen” Platform Trial General Info Brochure is available online!

Boosting Awareness

• On 5/23/22, a research notification about the Platform Trial was sent out to 11,440 registrants on the CDC’s National ALS Registry

• To view the CDC website or sign up for the National ALS Registry Newsletter:

Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: [QR Code]
ALS Link sign-up: [QR Code]

https://bit.ly/3r6Nd2L
https://bit.ly/3o2Ds3m

Upcoming Guest Speakers:

June 30th - Gale Kittle, RN, MPH (Director, Outcomes Measurement Training)
July 14th - Eufrosina Young, MD (Investigator at SUNY Upstate, New York)
The ALS Association/Northeast ALS Consortium Educational Webinar

Healey ALS Platform Trial Regimen E:
A Participant's Guide

Friday, June 17, 2022
5:00 - 6:00 PM EDT

The purpose of this webinar is to provide an overview of how SLS-005 (trehalose) may help to slow ALS and illustrate what potential participants can expect when enrolling in Regimen E of the Healey ALS Platform Trial. The presenters will review some of the unique aspects of the regimen related to the intravenous administration.

Recording Available: